Cencora, Inc. (NYSE: COR) has recently elected Frank Clyburn as a new independent director, effective October 1, 2024. With this addition, the Board of Directors will increase to thirteen members.
Mr. Clyburn brings extensive executive experience, particularly within the pharmaceutical industry, having recently served as Chief Executive Officer and as a member of the board of directors of International Flavors and Fragrances Inc. Prior to this, he spent decades in various leadership roles at leading pharmaceutical manufacturers, including Executive Vice President and President of Human Health at Merck.
Cencora's decision to elect Mr. Clyburn comes as the company continues to focus on long-term, sustainable growth. Steven H. Collis, Chairman, President & Chief Executive Officer of Cencora, expressed optimism about the valuable insights and perspectives Mr. Clyburn will bring to the board. He also highlighted the company's pharmaceutical-centric strategy and its anticipation of benefiting from Mr. Clyburn's expertise and guidance.
Cencora is a leading global pharmaceutical solutions organization with a workforce of over 46,000 worldwide. The company is ranked #10 on the Fortune 500 and #24 on the Global Fortune 500, with more than $250 billion in annual revenue.
The addition of Mr. Clyburn to the Board of Directors reflects Cencora's commitment to strengthening its leadership and leveraging the extensive industry experience of its directors as it continues to pursue its pharmaceutical-centric strategy. The market has reacted to these announcements by moving the company's shares -0.3% to a price of $237.06. If you want to know more, read the company's complete 8-K report here.
